Spark Therapeutics announces publication of positive follow-up data from phase 1 trial
Spark Therapeutics announced publication in The Lancet of long-term data from a Phase 1 trial of voretigene neparvovec (SPK-RPE65) which has received breakthrough therapy and orphan product designation for treatment of inherited retinal disease caused by mutations in the RPE65 gene. July 01, 2016